Prostaglandina f2α como indutor de ovulação em novilhas púberes.

O objetivo deste estudo foi avaliar o efeito da Prostaglandina F2&#945; (PGF) como indutor de ovulação em novilhas leiteiras. Treze novilhas púberes foram submetidas à sincronização de cio, e no Dia 5 da onda folicular receberam: 1) 1mg de BE (Grupo BE); 2) 500µg de PGF (Grupo PG) ou nenhum tratamento (Grupo Controle). Todas as novilhas ovularam, no entanto, os grupos BE e PG ovularam antes do Grupo CTL (P < 0,05). Estes resultados demonstram que a PGF é capaz de induzir a ovulação em novilhas leiteiras

Caracterização de polimorfismos no gene da leptina e do hormônio de crescimento em rebanhos bubalinos.

O Brasil possui o maior rebanho bubalino da América do Sul e das alternativas pecuárias destinadas à produção de carne e leite, o búfalo destaca-se pela qualidade nutricional da carne e do leite que produz. Buscando-se identificar polimorfismos tipo RFLP-PCR (Restriction fragment length polymorphism - Polimerase Chain Reaction) nos genes da leptina e do hormônio de crescimento (GH) foram genotipados 128 animais pertencentes a três grupos genéticos bubalinos selecionados para produção de leite. O DNA obtido foi submetido à amplificação com primers específicos estabelecidos para o estudo. Os produtos de PCR foram digeridos com enzimas de restrição para detecção dos polimorfismos leptina e GH visualizados em gel de agarose a 2,5%. A utilização da técnica de RFLP-PCR foi eficiente na genotipagem de bubalinos, e identificou a presença dos alelos W e P no gene LEPTINA, sendo o genótipo LEP WW predominante nas populações bubalinas estudadas. Em relação ao gene do hormônio do crescimento (GH) foi possível se identificar os genótipos GH WP e GHWW.bitstream/item/103409/1/bpd-71-bubalinos.pd

Weakly Supervised Localization and Learning with Generic Knowledge

ISSN:0920-5691ISSN:1573-140

Scenario of electricity production development in Latvia

Darba autore: Signe Allena. Bakalaura darbs: Latvijas elektroenerģijas ražošanas attīstības scenāriji. Zinātniskā darba vadītājs: Dr. oec., prof. Daina Šķiltere. Darba apjoms: 93 lpp., 15 tabulas, 49 attēli, 11 pielikumi, izmantoti 97 literatūras avoti. Darba mērķis: Izstrādāt Latvijas elektroenerģijas ražošanas attīstības scenārijus. Pētīšanas metodes: Scenāriju izstrādē un analīzē tika izmantota modificētā Delfi metode, trenda modeļi, kā arī kontrast - scenāriju metode un statistiskās apstrādes metodes. Darba rezultāts: Tika izstrādāti un novērtēti trīs iespējamie Latvijas elektroenerģijas ražošanas attīstības scenāriji. Atslēgas vārdi: scenāriju metode, scenāriji, modificētā Delfi metode, elektroenerģijas ražošana.Author: Signe Allena Bachelor’s paper: Scenarios of electricity production development in Latvia Adviser of the bachelor’s paper: Dr. oec., prof. Daina Šķiltere Size of the bachelor’s paper: 94 p., 15 tables, 49 figures, 11 appendices, used 96 literature sources. The aim of the work: Develop scenarios of electricity production progress in Latvia. Research methods: Within scenarios were used modified Delphi method, trend models, as well as contrast- scenario methodology and statistical processing methods. Result of the work: Developed and evaluated three potentional scenarios of electricity production development in Latvia. Keywords: scenarios planning, scenarios, modified Delphi method, production of electricity

The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: A 3-year, randomized, multicenter, double-blind, placebo-controlled study

Background: Placebo-controlled trials have found that angiotensin-converting enzyme inhibitors (ACEIs) decrease proteinuria and slow the progression of nondiabetic nephropathies. However, head-to-head comparisons of ACEIs and calcium channel blockers (CCBs) have shown conflicting results. Indeed, a recent metaanalysis concluded that there is still uncertainty about the greater renoprotection seen with ACEIs or angiotensin II receptor blockers in nondiabetic patients with renal disease, particularly when using true glomerular filtration rate (GFR) as the primary outcome. Objective: The objective of this 3-year, randomized, multicenter, double-blind, placebo-controlled study was to compare true GFR decline (measured by yearly 51Cr-EDTA blood clearance) in nondiabetic, nonnephrotic adult hypertensive patients with estimated creatinine clearance of 20 to 60 mL/min · 1.73 m2, when randomized to a CCB (amlodipine, 5-10 mg/d) or an ACEI (enalapril, 5-20 mg/d). Methods: Patients (aged 18-80 years) entered a 4-week placebo run-in washout period and previous antihypertensive drugs were tapered off over 2 weeks. Add-on treatments were atenolol (50-100 mg/d), loop diuretics (furosemide, 20-500 mg/d or torsemide, 5-200 mg/d), α-blockers (prazosin, 2.5-5 mg/d or doxazosin, 1-16 mg/d), and centrally acting drugs (rilmenidine, 1-2 mg/d or methyldopa, 250-500 mg/d). The primary end point was true GFR measured by yearly 51Cr-EDTA blood clearance. Secondary end points included a clinical composite of renal events and tolerability collected by a full clinical and laboratory evaluation at each study visit. Post hoc analyses for the change in GFR, proteinuria, and time to clinical events were also planned on baseline proteinuria subgroups (&lt;1 and ≥1 g/d) before unblinding the database. Results: Three hundred eighteen patients entered the run-in period and 263 patients (156 men/107 women; mean age, 58 years) were randomized to receive either amlodipine (5 mg/d, n = 132) or enalapril (5 mg/d, n = 131). Blood pressure declined from 165/102 mm Hg to 138/84 mm Hg and 138/85 mm Hg with amlodipine and enalapril, respectively (no between-group significance). Only 20.8% of the patients randomized to ACEI treatment received diuretics at the last observation. No statistically significant difference was found between amlodipine and enalapril in GFR decline (-4.92 and -3.98 mL/min · 1.73 m2, respectively, at last observation) and composite secondary end point after a median follow-up of 2.9 years, including in the subgroup of patients with proteinuria &gt;1 g/d at baseline. Protein excretion rate decreased significantly from baseline in patients taking enalapril plus diuretics (median -270 mg/d; P &lt; 0.001) but not in patients taking amlodipine plus diuretics (-25 mg/d at last observation). Conclusion: In this cohort of nondiabetic, nonnephrotic hypertensive patients, no statistically significant difference in true GFR decline was found over 3 years between amlodipine-treated patients and enalapril-treated patients with main add-on treatment with ß-blockers, including in the subgroup of patients with proteinuria &gt;1 g/d. © 2008 Excerpta Medica Inc